TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06336291
Drug: L19TNF
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 μg/kg
Study: NCT06336291
Drug: L19TNF
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg
Study: NCT06336291
Drug: L19TNF
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 μg/kg
Study: NCT06336291
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg/m2
Study: NCT06336291
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 110 mg/m2
Study: NCT06679881
Drug: Deucrictibant
Normalized name: Deucrictibant
DrugBank: Deucrictibant (DB18303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucrictibant extended-release tablet for once daily oral use
Study: NCT04762277
Drug: Spesolimab - solution for infusion
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT04762277
Drug: Placebo matching spesolimab - solution for infusion
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT04762277
Drug: Spesolimab- solution for injection
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT04762277
Drug: Placebo matching to spesolimab- solution for injection
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT06684314
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Study: NCT06685289
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, oral, twice daily, continuous medication for 6 months
Study: NCT05925621
Drug: Lecanemab
Normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study
Study: NCT06686797
Drug: PF-08049820
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution/suspension
Study: NCT06627179
Drug: Intravitreal Injection of Ultevursen
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: Ultevursen (DB17835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 doses over a 24-month period
Study: NCT06691685
Drug: ESO-T01 Injection
Normalized name: NY-ESO TCR therapeutic
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESO-T01 Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective BCMA-targeted CAR. ESO-T01 can be administered intravenously and produce CAR-T in vivo.
Study: NCT06628310
Drug: ABBV-400
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06628310
Drug: Budigalimab
Normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06628310
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion
Study: NCT06235203
Drug: Adjuvant therapy in control group,Toripalimab Injection and Gemcitabine based therapy
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ten courses of Toripalimab Injection and four to six courses of chemotherapy,or until unacceptable side effects.
Study: NCT04416451
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction:Rituximab will be administered per institutional guidelines once per week for 4 weeks at a dose of 375 mg/m\^2. Maintenance: In addition, patients will receive rituximab 375 mg/m2 starting on day 1 of the maintenance phase and repeated once every 3 months for 12 months (for a total of 4 infusions). On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Study: NCT04416451
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction: Starting one week after the last induction dose of rituximab (approximately week 5), venetoclax will be administered orally at a flat dose of 100 mg daily and escalating each week to a target dose of 800 mg daily on the following schedule:~* Week 1: 100 mg~* Week 2: 200 mg~* Week 3: 400 mg~* Week 4: 800 mg Maintenance: Following the 4-week induction phase ramp-up of venetoclax, patients will begin their target dose of 800 mg venetoclax daily and continue this dose during the 24- month maintenance treatment phase. On days when venetoclax and rituximab will both be administered, patients will take venetoclax prior to administration of rituximab.
Study: NCT06619860
Drug: VX-993
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration.
Study: NCT06619860
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules for oral administration.
Study: NCT06619587
Drug: Phase I Arm A
Normalized name: magnesium aluminometasilicate type I-A
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035
Study: NCT06619587
Drug: Phase I Arm B
Normalized name: magnesium aluminometasilicate type i-b
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose escalation and expansion arm, with protocol-defined dose(s) of GDC-7035 in combination with other anti-cancer therapies
Study: NCT06623890
Drug: Omaveloxolone
Normalized name: Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04864977
Drug: Basal Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants administered basal insulin
Study: NCT06554613
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine 5mg qd (once daily), q3w(every 3 weeks), oral therapy，Administered continuously for 6-8 weeks.
Study: NCT06554613
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab，Infused intravenously once every 3 weeks at a dose of 2mg/kg, with a continuous 21-day treatment period constituting one treatment cycle.
Study: NCT04925544
Drug: VK-2019
Normalized name: penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,
Study: NCT05026229
Drug: dasatinib plus consolidation chemotherapy with vincristine and prednisone
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction therapy, the patients in the 'Dasatinib, Vincristine and Prednisone' group will receive dasatinib and consolidation chemotherapy with vincristine and prednisone.
Study: NCT04550546
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600,000 U/mL of nystatin in a rinse suspension
Study: NCT04791969
Drug: Naltrexone Hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Oral Naltrexone, 50 mg
Study: NCT06382493
Drug: Tegoprazan-containing sequential H. pylori eradication therapy
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tegoprazan was administered, instead propton-pump inhibitor, as acid blockade in H. pylori eradication sequential therapy
Study: NCT06382493
Drug: Esomeprazole-containing sequential H. pylori eradication therapy
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole was administered as acid blockade in H. pylori eradication sequential therapy (conventional acid blockade method for sequential eradication therapy)
Study: NCT04827056
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Normalized name: dexmedetomidine Sublingual Product
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BXCL 501 40µg will be administered orally, as individual films in the SL space.
Study: NCT04827056
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
Normalized name: dexmedetomidine Sublingual Product
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BXCL 501 80µg will be administered orally, as individual films in the SL space.
Study: NCT04797013
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Study: NCT04797013
Drug: rhTNK-tPA
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to rhTNK-tPA or rt-PA in a 1:1 ratio.
Study: NCT05982873
Drug: ABBV-400
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT05092581
Drug: casirivimab+imdevimab
Normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose weight-based equivalent administered intravenously (IV)
Study: NCT04650321
Drug: Ocrelizumab at home
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive ocrelizumab infusion at home.
Study: NCT06679829
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 11 mg/kg, will be administered seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).
Study: NCT06679829
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: 70mg/m2 of melphalan on Day -2.~Arm B: SOC BSA based melphalan dosing at 140 or 200mg/m2 per treating physician on Day -2
Study: NCT06681662
Drug: Ephedrine Hydrochloride 30 mg/ml
Normalized name: ephedrine hydrochloride 30 MG/ML
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg/kg during induction.
Study: NCT06681662
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml during induction.
Study: NCT05696366
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.
Study: NCT05696366
Drug: Volagidemab
Normalized name: Volagidemab
DrugBank: Volagidemab (DB16421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).
Study: NCT04908137
Drug: 2-octyl cyanoacrylate
Normalized name: 2-octyl cyanoacrylate
DrugBank: 2-octyl cyanoacrylate (DB12040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
Study: NCT05894018
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg, orally, bid
Study: NCT04807569
Drug: Taking drug Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin at a dose of 0.4 mg x 1 time per day orally for 1 month.
Study: NCT06579690
Drug: 8.4% sodium bicarbonate solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion 8.4% solution The study drug will be contained in identical 25 mL glass vials (Neon Laboratories Ltd, Mumbai, India), administered intravenously as a single bolus dose.
Study: NCT06497647
Drug: Sulbutiamine
Normalized name: sulbutiamine
DrugBank: Sulbutiamine (DB13416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group B and combined with imipramine in group C
Study: NCT06497647
Drug: Imipramine
Normalized name: Imipramine
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.~it will be used alone in group A and combined with sulbutiamine in group C
Study: NCT05053334
Drug: Omalizumab Prefilled Syringe
Normalized name: omalizumab Prefilled Syringe
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg/ml of Omalizumab prefilled syringe
Study: NCT06051253
Drug: TDM-based infliximab intravenous therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (CT-P13, RemsimaTM) is intravenously given as an induction therapy at a dose of 5 mg/kg at week 0, 2, and 6. From week 14 to 46 (at week 14, 22, 30, 38, and 46), infliximab dose can be increased to 10 mg/kg, targeting trough level (TL) of infliximab 10 mcg/mL or over (If TL is 10 mcg/mL or over under treatment with 5 mg/kg infliximab, 5 mg/kg of infliximab is continued. If TL is lower than 10 mcg/mL, infliximab dose is increased to 10 mg/kg). Once infliximab dose was increased to 10 mg/kg, the next doses are fixed to 10 mg/kg.
Study: NCT06051253
Drug: Standard infliximab intravenous therapy
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (CT-P13, RemsimaTM) is intravenously administered at a dose of 5 mg/kg at week 0, 2, 6, 14, 22, 30, 38, and 46. Therapeutic dose monitoring (TDM, checking trough levels of infliximab) is performed at week 14, 22, 30, 38, and 46, but TDM results are not reflected in determining doses of infliximab.
Study: NCT05911958
Drug: SHR-A1811 for injection
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 for injection
Study: NCT04586010
Drug: Fenebrutinib
Normalized name: Fenebrutinib
DrugBank: Fenebrutinib (DB14785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive fenebrutinib.
Study: NCT04586010
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive teriflunomide.
Study: NCT05343702
Drug: priming with rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
Study: NCT06681194
Drug: Silver Nitrate
Normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Silver nitrate only study arm
Study: NCT06681194
Drug: triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Triamcinolone only study arm
Study: NCT06681194
Drug: Silver nitrate + triamcinolone
Normalized name: Silver Nitrate
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See Combination group study arm
Study: NCT05760937
Drug: BMS-986447
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06623630
Drug: Ciltacabtagene Autoleucel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT06625593
Drug: BG-C137
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06007430
Drug: Colostrum Capsule 500 mg (Colostrum® 500 mg Veg Capsules, nowfoods®, Illinois, USA)
Normalized name: COLOSTRUM
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand name: (Colostrum® 500 mg Veg Capsules) capsules per oral / once daily / 60 days duration.
Study: NCT06203145
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A reduction in serum FLCs level of more than 80% by day 14 of BCD is defined BCD-AutoHSCT group; A reduction in serum FLCs level of less than 80% by day 14 of BCD is defined BCD-KPD-AutoHSCT group.
Study: NCT06676774
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be instructed on correctly applying the intranasal study medication and will self-administer a single dose of 24 IU oxytocin under the supervision of unblinded study personnel.
Study: NCT05589363
Drug: ABC block with bupivacaine/liposomal bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution
Study: NCT05589363
Drug: ABC block with saline
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to receive an ABC block using normal saline
Study: NCT06624956
Drug: Crystalloid Infusion
Normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo
Study: NCT06672939
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04703920
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
Study: NCT05186558
Drug: penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months.
Study: NCT04703920
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
Study: NCT05196347
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In dapagliflozin arm, subjects will be received dapagliflozin 5 mg for 4 weeks. Uptitration to 10 mg will be done between 5 to 12th weeks, if eGFR dip \<20%.
Study: NCT04773236
Drug: sodium bicarbonate 8.4%
Normalized name: Sodium Bicarbonate 8.4% Intravenous Solution
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mixing the sodium bicarbonate with 2%lidocaine and 1:80.000 epinphrine using mixing pen (onset buffering system)
Study: NCT06372197
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following Oregon Psilocybin Services (OPS) rules, participants will be placed in cohorts of five to six, which whom they will do two 90-minute preparation session, two psilocybin sessions, and two 90-minute integration sessions. All sessions will be guided by two licensed facilitators.
Study: NCT04773236
Drug: 2%lidocaine with 1:80.000 epinphrine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection
Study: NCT05057949
Drug: Larotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotinib Capsules
Study: NCT05057949
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin Capsules
Study: NCT05057949
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole Capsules
Study: NCT06684041
Drug: HRS-5965 capsule
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-5965 capsule
Study: NCT06683014
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).
Study: NCT05642572
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05642572
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05035082
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration The doctor will give a prescription for the medicine and tell how to take it.
Study: NCT05906121
Drug: lidocaine-ketamine infusions
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine and ketamine are infused over a period of 30 minutes. The dosage of lidocaine is 4mg/kg is maintained throughout the infusions, and the dosage of ketamine is increased within the first three infusions from 0.15mg/kg at the first, to 0.25mg/kg at the second and 0.5mg/kg at the third infusion. In case patients already experiencing sufficient analgesic effect and/or improvement in quality of life after the 1st or 2nd infusion or if side effects do not allow a further dose increase, no further step up of ketamine dosage is made. As a part of this study, at the end of the first, second and third infusion, side effects will be screened using customized questionnaires (SF - MPQ, BDI-II)